nach oben

Erschienen in:

12.06.2022 | Original Article

Randomized prospective trial of the severity of irritative symptoms after HoLEP vs ThuFLEP

verfasst von: Dmitry Enikeev, Mark Taratkin, Diana Babaevskaya, Andrey Morozov, Vladislav Petov, Roman Sukhanov, Evgeny Shpot, Vincent Misrai, Denis Chinenov, Mikhail Enikeev, Thomas Herrmann

Erschienen in: World Journal of Urology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the short-term postoperative functional outcomes and severity of irritative symptoms following holmium and thulium fiber laser enucleation (HoLEP and ThuFLEP).

Methods

This prospective randomized single-blinded study was performed in accordance with CONSORT. The inclusion criteria were IPSS > 20 or Qmax < 10 ml/s. Patients were randomized between HoLEP and ThuFLEP. Demographics, objective data (PSA, prostate volume, etc.), data on urinary and sexual function (IPSS, IIEF, QoL, QUID, Qmax, ICIQ-MLUTS) were collected. Detailed perioperative information and postoperative data on functional outcomes at 1, 2, 3, 4, 6, 8, 10, 12 weeks and 6 months were collected.

Results

Data on 163 participants were included (77—HoLEP, 86—ThuFLEP). No differences were found in surgery duration; number of postoperative complications (Clavien–Dindo I-III), catheterization time and hospital stay. Functional outcomes up to 6 months didn’t differ between the groups (IPPS, IIEF, QoL, QUID, ICIQ-MLUTS, Qmax, p > 0.05). Total ICIQ‐MLUTS, bother and voiding scores at 1 and 3 months significantly increased compared with the baseline in both groups (p < 0.05). No difference between the groups were observed. In HoLEP the SUI series rate was 1.3% and 1.3% after 3 and 6 months following the procedure; in ThuFLEP: it was 3.5% and 2.3% respectively (p = 0.35 and p = 0.54).

Conclusion

The preliminary results of the study showed no apparent differences in functional outcomes (IPSS, Qmax), rate of SUI or irritative symptoms. Both ThuFLEP and HoLEP are efficient ways of treating benign prostatic obstruction. Both surgeries are comparable in terms of duration and postoperative complication rates.

Nur mit Berechtigung zugänglich

EAU Guidelines: management of non-neurogenic Male LUTS | Uroweb n.d. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5 (Accessed February 5, 2021)

Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-Year Follow-Up Results of a Randomised Clinical Trial. Eur Urol 53:160–168. https://doi.org/10.1016/j.eururo.2007.08.036CrossRefPubMed

Benign Prostatic Hyperplasia (BPH) Guideline - American Urological Association n.d. https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline (Accessed July 27, 2021)

Cornu J-NN, Ahyai S, Bachmann A, De La Rosette J, Gilling P, Gratzke C, et al (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. vol. 67. Elsevier https://doi.org/10.1016/j.eururo.2014.06.017

Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G (2004) A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. J Urol 171:1773–1781. https://doi.org/10.1097/01.ju.0000113494.03668.6dCrossRefPubMed

Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F et al (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58:384–397. https://doi.org/10.1016/j.eururo.2010.06.005CrossRefPubMed

Enikeev D, Glybochko P, Okhunov Z, Alyaev Y, Rapoport L, Tsarichenko D et al (2018) Retrospective analysis of short-term outcomes after monopolar versus laser endoscopic enucleation of the prostate: a single center experience. J Endourol 32:417–423. https://doi.org/10.1089/end.2017.0898CrossRefPubMed

Enikeev D, Rapoport L, Gazimiev M, Allenov S, Inoyatov J, Taratkin M et al (2020) Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80 cc) benign prostate hyperplasia: a prospective analysis. World J Urol 38:167–173. https://doi.org/10.1007/s00345-019-02757-zCrossRefPubMed

Peyronnet B, Robert G, Comat V, Rouprêt M, Gomez-Sancha F, Cornu J-NN, et al (2017) Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: a comparison between GreenLight 532-nm and holmium lasers. World J Urol 35:973–983. https://doi.org/10.1007/s00345-016-1957-5.

10.

Herrmann TRWW (2016) Enucleation is enucleation is enucleation is enucleation. World J Urol 34:1353–1355. https://doi.org/10.1007/s00345-016-1922-3CrossRefPubMed

11.

Pallauf M, Kunit T, Ramesmayer C, Deininger S, Herrmann TRW, Lusuardi L. Endoscopic enucleation of the prostate (EEP). The same but different—a systematic review. World J Urol 2021. https://doi.org/10.1007/s00345-021-03705-6.

12.

Fried NMM, Murray KEE (2005) New technologies in endourology: High-power thulium fiber laser ablation of urinary tissues at 1.94 μm. J Endourol 19:25–31. https://doi.org/10.1089/end.2005.19.25CrossRefPubMed

13.

Enikeev D, Netsch C, Rapoport L, Gazimiev M, Laukhtina E, Snurnitsyna O et al (2019) Novel thulium fiber laser for endoscopic enucleation of the prostate: A prospective comparison with conventional transurethral resection of the prostate. Int J Urol 26:1138–1143. https://doi.org/10.1111/iju.14115CrossRefPubMed

14.

Sealed Envelope | Power calculator for binary outcome non-inferiority trial n.d. https://www.sealedenvelope.com/power/binary-noninferior/ (Accessed February 5, 2021)

15.

Enikeev D, Taratkin M, Laukhtina E, Alekseeva T, Snurnitsyna O, Potoldykova N et al (2019) En bloc and two-lobe techniques for laser endoscopic enucleation of the prostate: retrospective comparative analysis of peri- and postoperative outcomes. Int Urol Nephrol 51:1969–1974. https://doi.org/10.1007/s11255-019-02259-2CrossRefPubMed

16.

Taratkin M, Kovalenko A, Laukhtina E, Paramonova N, Spivak L, Wachtendorf LJJ et al (2020) Ex vivo study of Ho:YAG and thulium fiber lasers for soft tissue surgery: which laser for which case? Lasers Med Sci. https://doi.org/10.1007/s10103-020-03189-7CrossRefPubMed

17.

Bach T, Wendt-Nordahl G, Michel MS, Herrmann TRW, Gross AJ (2009) Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27:541–545. https://doi.org/10.1007/s00345-008-0370-0CrossRefPubMed

18.

Becker B, Herrmann TRW, Gross AJ, Netsch C (2018) Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate for the treatment of large volume prostates: preliminary 6-month safety and efficacy results of a prospective randomized trial. World J Urol 36:1663–1671. https://doi.org/10.1007/s00345-018-2321-8CrossRefPubMed

19.

Herrmann TRW, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M et al (2010) Thulium laser enucleation of the prostate (ThuLEP): Transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 28:45–51. https://doi.org/10.1007/s00345-009-0503-0CrossRefPubMed

20.

Enikeev D, Glybochko P, Rapoport L, Gahan J, Gazimiev M, Spivak L et al (2018) A randomized trial comparing the learning curve of 3 endoscopic enucleation techniques (HoLEP, ThuFLEP, and MEP) for BPH Using Mentoring Approach—Initial Results. Urology 121:51–57. https://doi.org/10.1016/j.urology.2018.06.045CrossRefPubMed

21.

Fried NM (2006) Therapeutic applications of lasers in urology: an update. Expert Rev Med Devices 3:81–94. https://doi.org/10.1586/17434440.3.1.81CrossRefPubMed

22.

Romero-Otero J, García-Gómez B, García-González L, García-Rojo E, Abad-López P, Justo-Quintas J et al (2020) Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice. BJU Int 126:177–182. https://doi.org/10.1111/bju.15028CrossRefPubMed

23.

Houssin V, Olivier J, Brenier M, Pierache A, Laniado M, Mouton M et al (2020) Predictive factors of urinary incontinence after holmium laser enucleation of the prostate: a multicentric evaluation. World J Urol. https://doi.org/10.1007/s00345-020-03169-0CrossRefPubMed

24.

Fallara G, Capogrosso P, Schifano N, Costa A, Candela L, Cazzaniga W et al (2020) Ten-year follow-up results after holmium laser enucleation of the prostate. Eur Urol Focus 7:5–10. https://doi.org/10.1016/j.euf.2020.05.012CrossRef

25.

Elmansy HM, Kotb A, Elhilali MM (2011) Holmium laser enucleation of the prostate: Long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol 186:1972–1976. https://doi.org/10.1016/j.juro.2011.06.065CrossRefPubMed

26.

Enikeev D, Okhunov Z, Rapoport L, Taratkin M, Enikeev M, Snurnitsyna O et al (2019) Novel thulium fiber laser for enucleation of prostate: a retrospective comparison with open simple prostatectomy. J Endourol 33:16–21. https://doi.org/10.1089/end.2018.0791CrossRefPubMed

27.

Herrmann TRW, Gravas S, de la Rosette JJ, Wolters M, Anastasiadis AG, Giannakis I (2020) Lasers in transurethral enucleation of the prostate—Do we really need them. J Clin Med 9:1412. https://doi.org/10.3390/jcm9051412CrossRefPubMedCentral

28.

Morozov A, Taratkin M, Kozlov V, Tarasov A, Bezrukov E, Enikeev M et al (2020) Retrospective assessment of endoscopic enucleation of prostate complications: a single-center experience of more than 1400 patients. J Endourol 34:192–197. https://doi.org/10.1089/end.2019.0630CrossRefPubMed

29.

Nottingham CU, Large T, Agarwal DK, Rivera ME, Krambeck AE (2021) Comparison of newly optimized Moses technology vs standard holmium:YAG for endoscopic laser enucleation of the prostate. J Endourol 35:1393–1399. https://doi.org/10.1089/end.2020.0996CrossRefPubMed

30.

Nevo A, Faraj KS, Cheney SM, Moore JP, Stern KL, Borofsky M et al (2021) Holmium laser enucleation of the prostate using Moses 2.0 vs non-Moses: a randomised controlled trial. BJU Int 127:553–9. https://doi.org/10.1111/bju.15265CrossRefPubMed

31.

Rücker F, Lehrich K, Böhme A, Zacharias M, Ahyai SA, Hansen J (2021) A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe. World J Urol 39:2337–45. https://doi.org/10.1007/s00345-021-03598-5CrossRefPubMed

Titel: Randomized prospective trial of the severity of irritative symptoms after HoLEP vs ThuFLEP
verfasst von: Dmitry Enikeev
Mark Taratkin
Diana Babaevskaya
Andrey Morozov
Vladislav Petov
Roman Sukhanov
Evgeny Shpot
Vincent Misrai
Denis Chinenov
Mikhail Enikeev
Thomas Herrmann
Publikationsdatum: 12.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 8/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-022-04046-8

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Randomized prospective trial of the severity of irritative symptoms after HoLEP vs ThuFLEP